Literature DB >> 10699117

Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children.

K DeBella1, J Szudek, J M Friedman.   

Abstract

OBJECTIVE: The National Institutes of Health (NIH) Diagnostic Criteria for neurofibromatosis 1 (NF1) are very useful clinically, but some individuals who are later shown to have NF1 cannot be diagnosed in early childhood using these criteria. The aim of this study is to determine the value of the NIH Diagnostic Criteria for NF1 in early childhood, to determine the age at which diagnosis can confidently be made, and to clarify the age at onset of the cardinal clinical features used in the NIH Diagnostic Criteria.
METHODS: We studied 1893 NF1 patients under 21 years old from the National Neurofibromatosis Foundation International Database to determine the age at which the features included in the NIH Diagnostic Criteria appear.
RESULTS: Approximately 46% of sporadic NF1 cases fail to meet the NIH Diagnostic Criteria by 1 year of age. Nearly all (97%; 95% confidence interval: 94-98) NF1 patients meet the criteria for diagnosis by 8 years old, and all do so by 20 years old. The usual order of appearance of the clinical features listed as NIH criteria is café-au-lait macules, axillary freckling, Lisch nodules, and neurofibromas. Symptomatic optic glioma is usually diagnosed by 3 years old, and characteristic osseous lesions are usually apparent within the first year of life.
CONCLUSION: The diagnosis of NF1 cannot always be made in young children using the NIH Diagnostic Criteria. Modification of these criteria may be necessary for children under 8 years old.

Entities:  

Mesh:

Year:  2000        PMID: 10699117     DOI: 10.1542/peds.105.3.608

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  100 in total

1.  A child with axillary freckling and café au lait spots.

Authors:  Stephen Wainer
Journal:  CMAJ       Date:  2002-08-06       Impact factor: 8.262

2.  Phenotypic variability among café-au-lait macules in neurofibromatosis type 1.

Authors:  Kevin P Boyd; Liyan Gao; Rui Feng; Mark Beasley; Ludwine Messiaen; Bruce R Korf; Amy Theos
Journal:  J Am Acad Dermatol       Date:  2010-06-03       Impact factor: 11.527

3.  Perioperative management of neurofibromatosis type 1.

Authors:  Charles J Fox; Samir Tomajian; Aaron J Kaye; Stephanie Russo; Jacqueline Volpi Abadie; Alan D Kaye
Journal:  Ochsner J       Date:  2012

Review 4.  Genetics of hereditary neurological disorders in children.

Authors:  Yue Huang; Sui Yu; Zhanhe Wu; Beisha Tang
Journal:  Transl Pediatr       Date:  2014-04

Review 5.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

6.  High prevalence of elevated blood pressure among children with neurofibromatosis type 1.

Authors:  Tom Dubov; Hagit Toledano-Alhadef; Gil Chernin; Shlomi Constantini; Roxana Cleper; Shay Ben-Shachar
Journal:  Pediatr Nephrol       Date:  2015-08-28       Impact factor: 3.714

7.  Gastrointestinal bleeding and cutaneous nodules.

Authors:  Alka Mittal; Daniel Felter; S Michelle Shiller; A David McCollum; Jeffrey P Lamont; Damien Mallat
Journal:  Proc (Bayl Univ Med Cent)       Date:  2008-07

Review 8.  Imaging of cancer predisposition syndromes.

Authors:  Mary-Louise C Greer
Journal:  Pediatr Radiol       Date:  2018-08-04

9.  Treatment of neurofibromatosis type 1.

Authors:  Caterina Sabatini; Donatella Milani; Francesca Menni; Gianluca Tadini; Susanna Esposito
Journal:  Curr Treat Options Neurol       Date:  2015-06       Impact factor: 3.598

10.  Effects of resveratrol on the proliferation and osteogenic differentiation of deciduous dental pulp stem cells from neurofibromatosis type 1 patient.

Authors:  Claudinéia Pereira Maranduba; Gustavo Torres Souza; Antônio Márcio Resende do Carmo; José Marcelo Sallabert de Campos; Nádia Rezende Barbosa Raposo; Marcelo de Olivera Santos; Carlos Magno da Costa Maranduba; Fernando de Sá Silva
Journal:  Childs Nerv Syst       Date:  2020-11-20       Impact factor: 1.475

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.